Brokerages Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $53.75

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $53.75.

A number of equities research analysts have weighed in on the company. Zacks Research raised XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Lucid Cap Mkts lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Weiss Ratings lowered XOMA Royalty from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday. Finally, HC Wainwright lowered XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a report on Thursday, April 30th.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $41.75 on Friday. The stock has a market capitalization of $523.55 million, a PE ratio of 28.60 and a beta of 0.90. XOMA Royalty has a 52-week low of $22.29 and a 52-week high of $42.81. The stock’s 50-day moving average price is $34.90 and its 200 day moving average price is $30.60. The company has a quick ratio of 3.37, a current ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The firm had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $11.13 million. As a group, equities research analysts forecast that XOMA Royalty will post 0.94 EPS for the current year.

Institutional Investors Weigh In On XOMA Royalty

A number of institutional investors have recently added to or reduced their stakes in XOMA. JPMorgan Chase & Co. boosted its stake in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of XOMA Royalty during the 4th quarter worth approximately $27,000. Dimensional Fund Advisors LP boosted its stake in shares of XOMA Royalty by 4.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after acquiring an additional 1,269 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.